Other. For the first quarter of fiscal 2014, the Company recorded dividend income of RMB8.7 million ($1.4 million), which derived from the Company's equity investment in the Shandong Cord Blood Bank and the Company's equity investment in Cordlife Group Limited ("Cordlife"). During the first quarter of fiscal 2013, the Company recorded dividend income of RMB2.4 million from Cordlife.
NET INCOME ATTRIBUTABLE TO THE COMPANY'S SHAREHOLDERS. Profit before tax for the first quarter of fiscal 2014 increased by 10.5% to RMB44.4 million ($7.2 million) as a result of improved operating income along with the recorded dividend income, which partially offset the increase in interest expense. Net income attributable to the Company's shareholders for the first quarter of fiscal 2014 increased by 5.8% to RMB32.9 million ($5.4 million), representing a net margin of 25.6%.
EARNINGS PER SHARE. The terms of the convertible notes issued to KKR and Golden Meditech Holdings Limited ("Golden Meditech") provide each party with the ability to participate in any Excess Cash Dividend2. Therefore, the calculation of basic and diluted EPS has taken into consideration the effect of such participating rights equal to RMB0.05 ($0.01) for the first quarter of fiscal 2014. Basic and diluted earnings per ordinary share for the first quarter of fiscal 2014 were RMB0.40 ($0.07).
LIQUIDITY. As of June 30, 2013, the Company had cash and cash equivalents of RMB1,560.0 million ($254.2 million) compared to RMB1,494.1 million as of March 31, 2013. The Company had total debt of RMB800.1 million ($130.4 million) as of June 30, 2013. Operating cash inflow for the first quarter of fiscal 2014 amounted to RMB108.7 mil
|SOURCE China Cord Blood Corporation|
Copyright©2012 PR Newswire.
All rights reserved